HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
Key Details
- 1AI-CVD is cleared via FDA 510(k) by HeartLung Corporation.
- 2The platform analyzes CT images of the chest and abdomen to screen for various diseases.
- 3No additional CT sequences, radiation, or contrast are needed to use the tool.
- 4Automatically quantifies clinical measurements for cardiovascular and non-cardiovascular conditions.
- 5Diseases targeted include coronary artery disease, heart failure, atrial fibrillation, stroke, osteoporosis, liver steatosis, and diabetes.
Why It Matters
The clearance marks a significant step for opportunistic AI in radiology, enabling wider disease detection from standard CT scans without extra imaging, doses, or disruptions. This has the potential to improve early diagnosis and make radiology workflows more efficient.
Source
Radiology Business
Related News
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
•AuntMinnie
AI Increases Lung Nodule Detection on LDCT but Not Speed
AI assistance raised detection rates of actionable lung nodules on LDCT but did not reduce interpretation time for radiologists.
•Radiology Business
Prospective Study Confirms AI Boosts Lung Nodule Detection in CT Screening
A new prospective trial finds AI assistance significantly increases detection of suspicious lung nodules in low-dose chest CT screenings.